# Philips account plan

> Royal Philips is an Amsterdam-based health technology company with EUR 17,834 million of 2025 sales and about 65,000 employees.

## At a glance

Royal Philips (Koninklijke Philips N.V.) is a health technology company that sells imaging, interventional, monitoring and informatics platforms to hospitals and health systems, and grooming, oral care and mother-and-child products to consumers. It is headquartered in Amsterdam, present in 71 countries and employs about 65,000 people, with R&D centred on Eindhoven, Cambridge (US), Bengaluru and Beijing. In FY2025 sales were EUR 17,834 million (-1% nominal, +2% comparable), Adjusted EBITA EUR 2,195 million (12.3% margin) and net income EUR 897 million, after a loss of EUR (698) million in 2024. Health systems revenue mixes product sales, service fees, per-procedure fees, software licences and as-a-service contracts; Personal Health sells through retailers, online platforms and direct-to-consumer.

## Business units

- **Diagnosis & Treatment** (48% of 2025 group sales (EUR 8,531 million)): Precision Diagnosis (MRI, ultrasound, CT, diagnostic X-ray) and Image Guided Therapy (Azurion interventional systems and devices), sold to hospitals directly and through distributors. Comparable sales were flat in 2025 and grew 2% in Q2 2026, with Image Guided Therapy growing high-single-digit for the 22nd consecutive quarter while Precision Diagnosis declined low-single-digit, weighed by China. Led by Bert van Meurs and Jie Xue.
- **Connected Care** (28% of 2025 group sales (EUR 5,076 million)): Monitoring (hospital patient monitoring, ambulatory monitoring), Enterprise Informatics (imaging and clinical informatics, cloud on AWS) and Sleep & Respiratory Care, for hospitals, ambulatory and home care providers. Comparable sales rose 3% in 2025; Enterprise Informatics is moving customers from on-premise to cloud and SaaS. Led by Julia Strandberg, with Shez Partovi heading Enterprise Informatics.
- **Personal Health** (21% of 2025 group sales (EUR 3,673 million)): Personal Care (shavers, OneBlade, Lumea IPL), Oral Healthcare (Sonicare) and Mother and Child Care (Philips Avent), sold through retailers, online platforms and the Philips online store. It grew 8% comparable in 2025 with an 18.0% Adjusted EBITA margin, and 8% again in Q2 2026. Led by Deeptha Khanna.
- **Other** (3% of 2025 group sales (EUR 554 million)): Innovation & Design, IP royalties and central costs. Sales fell from EUR 611 million in 2024, mainly on lower royalty income.

## Strategic priorities

- **Profitable growth plan 2026-2028**: Mid-single-digit comparable sales CAGR, a mid-teens Adjusted EBITA margin in 2028 and EUR 4.5-5.0 billion of cumulative free cash flow, set at the Capital Markets Day on February 10, 2026.
- **Disproportionate focus on Monitoring and Interventional**: Segment-specific strategies replace the earlier 70-30 split; Image Guided Therapy targets mid-to-high-single-digit growth and an adjusted EBITA above 20% by 2028, and Connected Care a clear path to mid-teens margins.
- **AI and platform innovation**: AI-powered platforms such as Azurion Eye, Verida spectral CT, helium-free 3.0T MRI and the ECG AI Marketplace, built on an installed base of more than 2.5 million systems, with partners AWS, Nvidia and Mayo Clinic.
- **EUR 1.5 billion productivity programme**: Savings over 2026-2028 from cost competitiveness (CT platforms from seven to three), central functions cut 15% to 20% toward first-quartile benchmarks, and AI; EUR 258 million delivered year-to-date by Q2 2026.
- **Patient safety and quality**: Respironics remains under the US consent decree, with no new sleep therapy or respiratory device sales in the US; an FDA warning letter followed inspections in September 2025. US sleep therapy re-entry is not included in the plan.
- **Regional growth engines**: North America is the core growth engine, with large health systems seeking fewer, deeper partnerships; Europe posted double-digit order growth in Q2 2026; India, Indonesia and Saudi Arabia are named growth markets while China is handled selectively.

## Latest results

In Q2 2026 Philips posted sales of EUR 4,360 million, +1% nominal and +4% comparable, with growth in all three segments. Adjusted EBITA was EUR 717 million, a 16.4% margin that includes a US tariff refund benefit; the underlying margin was 12.2%. Comparable order intake fell 1% as large North American Monitoring orders moved into Q3, after six consecutive quarters of growth, while the equipment order book stayed at a record level. First-half 2026 sales were EUR 8,265 million (+4% comparable). Philips reiterated 2026 comparable sales growth of 3%-4.5% and raised its Adjusted EBITA margin outlook to 13.5%-14.0% (including about 1% from the refund) and free cash flow to EUR 1.5-1.7 billion.

## Investments and deals

- **SpectraWAVE acquisition**: Coronary vascular imaging company acquired January 15, 2026; goodwill of EUR 169 million and contingent consideration of up to EUR 65 million tied to regulatory and revenue milestones.
- **US manufacturing and R&D**: USD 150 million announced to expand US manufacturing and R&D, including ultrasound in Reedsville, Pennsylvania and Image Guided Therapy in Plymouth, Minnesota.
- **Capital expenditure**: Net capital expenditures of EUR 660 million in 2025, in line with 2024; R&D held at around 9% of sales with fewer, bigger programmes.
- **Divestments**: Emergency Care sold in 2025 (now Heartstream) among two divestments for EUR 77 million; the electronic medical records business was divested in Q2 2026, with a EUR 99 million gain.

## Challenges and risks

- **Tariffs and cost inflation**: Tariffs rose from about 1% to about 3% of cost of sales in 2025; e-components, freight and energy inflation cut the underlying Diagnosis & Treatment margin to 9.3% in Q2 2026.
- **China**: Health systems sales in China are weak as centralised procurement expands; Precision Diagnosis declined low-single-digit partly because of China.
- **Respironics legal and regulatory exposure**: Investigations by the SEC, DoJ, State Attorneys General and Australia's TGA continue, alongside securities claims and an Amsterdam Enterprise Chamber inquiry request.
- **Slow informatics transition**: Enterprise Informatics sales declined mid-single-digit in Q2 2026 as customers move to cloud; orders take 12 to 18 months to turn into revenue.
- **Order-to-sales conversion**: Larger deals and constrained installation capacity slow the conversion of orders into sales.

## What leadership says

> "Today marks the beginning of a next phase for Philips. We have stabilised the company, significantly improved our culture, our team and the fundamentals of our business." — Roy Jakobs, CEO, Philips Capital Markets Day 2026, February 10, 2026

> "In healthcare, AI is augmenting instead of replacing people" — Roy Jakobs, CEO, Philips Capital Markets Day 2026, February 10, 2026

> "We delivered another solid quarter with comparable sales growth of 4%, driven by all business segments" — Roy Jakobs, CEO, Philips Quarterly Report Q2 2026, July 27, 2026

> "In 2025, we delivered on our commitments and drove performance every quarter" — Charlotte Hanneman, CFO, Philips Annual Report 2025


## Where a supplier can help

- **Productivity and central-function savings**: The EUR 1.5 billion productivity programme and the 15% to 20% central-functions reduction open room for suppliers of automation, AI agents and process tooling that cut cost per transaction.
- **Supply chain and tariff mitigation**: Tariff and e-component inflation, plus the regionalisation and dual-sourcing push, favour suppliers of components, logistics and sourcing analytics that help localise production.
- **Cloud and AI informatics**: The move of Enterprise Informatics to cloud and SaaS and the AI platform agenda create demand for cloud, data, cybersecurity and AI regulatory-compliance partners.
- **Installation and service capacity**: Constrained installation capacity slows order-to-sales conversion; field service, installation and project-management partners could help turn the record order book into revenue.
- **Quality and regulatory compliance**: The Respironics consent decree and the FDA warning letter make quality management, regulatory documentation and audit tooling a standing need.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Philips Annual Report 2025](https://www.results.philips.com/app/uploads/2026/04/PhilipsFullAnnualReport2025-English.pdf)

Annual report · 2026-02-19

- Royal Philips is a focused health technology company organised in three segments: Diagnosis & Treatment (48% of 2025 sales), Connected Care (28%) and Personal Health (21%), plus Other (3%: royalties, innovation, central costs); about 65,000 employees, headquartered in Amsterdam.
- FY2025 sales EUR 17,834 million, down 1% nominally (currency) but up 2% comparable; comparable order intake grew 6% (1% in 2024).
- Adjusted EBITA EUR 2,195 million, margin 12.3% (11.5% in 2024); income from operations EUR 1,424 million; net income EUR 897 million after a loss of EUR (698) million in 2024; free cash flow EUR 512 million, held down by EUR 1,025 million of Respironics settlement payments.
- Personal Health was the growth engine (+8% comparable, 18.0% Adjusted EBITA margin); Connected Care +3% (10.7%); Diagnosis & Treatment flat (11.7%), with Image Guided Therapy growing mid-single-digit and Precision Diagnosis declining low-single-digit.
- North America grew 3% comparable and Growth geographies 5%; China saw lower sales on adverse market conditions; tariffs rose from about 1% to about 3% of cost of sales.
- 2026 outlook: comparable sales growth 3%-4.5%, Adjusted EBITA margin 12.5%-13.0%, free cash flow EUR 1.3-1.5 billion. 2026-2028 targets: mid-single-digit comparable sales CAGR, mid-teens Adjusted EBITA margin in 2028, EUR 4.5-5.0 billion cumulative free cash flow, EUR 1.5 billion productivity savings.
- Strategic focus on platform innovation powered by AI (helium-free 3.0T MRI, Verida spectral CT, ECG AI Marketplace) and on its strongholds Image Guided Therapy, Monitoring, Ultrasound and Personal Health; SpectraWAVE (coronary imaging) acquired January 15, 2026; Emergency Care sold (now Heartstream); USD 150 million US manufacturing and R&D investment.
- Patient safety and quality remain the number one priority: Respironics still operates under the US consent decree (no new CPAP/BiPAP sales in the US) and an FDA warning letter in September 2025 followed inspections of nine facilities.
- Top risks: geopolitics, tariffs and US-China tensions, keeping pace with AI and health informatics, quality and regulatory compliance, supply chain resilience; dividend kept at EUR 0.85 per share.

### [Philips Quarterly Report Q2 2026 (including semi-annual report 2026)](https://www.results.philips.com/app/uploads/2026/07/philips-second-quarter-results-2026-report.pdf)

Interim report · 2026-07-27

- Q2 2026 group sales EUR 4,360 million, +1% nominal and +4% comparable, with growth in all segments; comparable order intake fell 1% because certain large Connected Care orders shifted into Q3.
- Adjusted EBITA EUR 717 million, margin 16.4%, including a US tariff refund benefit of effectively 4.2 points; income from operations EUR 609 million including a EUR 186 million tariff refund benefit; net income EUR 386 million.
- Segments: Diagnosis & Treatment +2% comparable (Image Guided Therapy high-single-digit growth, Precision Diagnosis low-single-digit decline), Connected Care +2% (Monitoring mid-single-digit), Personal Health +8%.
- Growth geographies +13% comparable (Central Eastern Europe, Latin America, Indian subcontinent); Mature geographies +1%, North America +3%, Western Europe -2%.
- First half 2026: sales EUR 8,265 million, +4% comparable; Adjusted EBITA EUR 1,069 million, 12.9% including effectively 2.2 points of tariff refund.
- 2026 outlook: comparable sales growth 3%-4.5% reiterated; Adjusted EBITA margin raised to 13.5%-14.0% (including about 1% from the refund) and free cash flow to EUR 1.5-1.7 billion.
- Productivity savings of EUR 132 million in the quarter; on track for EUR 1.5 billion under the 2026-2028 programme.
- Innovations and deals: SmartIQ ultra-low-dose for Azurion, Titanion MR, 4D MR for radiation therapy; Poland modernisation of more than 200 hospitals; Region Stockholm hospital-at-home (up to 15,000 patients a year).
- Respironics investigations by the SEC, DoJ, State Attorneys General and Australia's TGA continue; an Amsterdam Enterprise Chamber decision on an inquiry into the recall is expected toward the end of Q3.

### [Philips Q2 2026 results conference call transcript](https://www.results.philips.com/app/uploads/2026/07/Transcript-Philips-second-quarter-2026-results-28-July-2026.pdf)

Executive talk · Roy Jakobs, CEO (with Charlotte Hanneman, CFO) · 2026-07-28

- CEO Roy Jakobs and CFO Charlotte Hanneman present Q2 2026 (call held July 28, 2026, brought forward after the results were inadvertently published the evening before): comparable sales +4%, Adjusted EBITA margin 16.4% including the US tariff refund, 12.2% underlying.
- Order intake fell 1% after six consecutive quarters of growth as large North American Monitoring orders moved to Q3; the equipment order book is at a record level and Jakobs expects order growth to return to mid-single digits in Q3 and beyond.
- Regional view: North America strong (double-digit order growth over 12 months, HealthTrust 2026 Capital Supplier of the Year), Europe double-digit order growth (Poland, Karolinska, UK, Germany), China weak in health systems as centralised procurement expands; India is "really picking up a double-digit contribution".
- Diagnosis & Treatment margin excluding the refund fell to 9.3% on cost inflation, tariffs, currency and China; Image Guided Therapy grew for the 22nd consecutive quarter.
- Personal Health +8.5% comparable; new Sonicare ranges took back US market leadership in power toothbrushes; distribution gains at Walmart, Costco and pharmacies.
- Enterprise Informatics sales declined mid-single-digit while customers move to cloud; orders take 12 to 18 months to turn into revenue; the electronic medical records business was divested in Q2.
- Productivity EUR 258 million year-to-date; AI used internally (Illuminate makes concept development 50% faster, NOVA cuts requirements drafting time by around one-third).
- Full-year outlook: underlying Adjusted EBITA margin 12.5%-13%, Q3 margin below prior year, strong Q4 step-up; net debt EUR 5.7 billion, leverage 1.8x.

### [Philips Capital Markets Day 2026 transcript](https://www.philips.com/c-dam/corporate/about-philips/investors/calendar/2026/CMD_2026_Transcript.pdf)

Executive talk · Roy Jakobs, CEO · 2026-02-10

- Capital Markets Day (February 10, 2026): CEO Roy Jakobs says Philips has "stabilised the company" and enters "a next phase" focused on profitable growth; targets mid-single-digit sales CAGR, mid-teens Adjusted EBITA margin in 2028 and EUR 4.5-5 billion cumulative free cash flow over 2026-2028.
- Strategy in three pillars: focused value creation by segment (disproportionate investment in Monitoring and Interventional), innovation through data, AI and platforms, and disciplined execution with a step-up in commercial excellence.
- Platform advantage: installed base of more than 2.5 million systems, reaching 80% of top hospitals globally; partnerships with AWS (cloud diagnostics), Nvidia (foundation AI model for MRI), Mayo Clinic (cardiac MRI exam time from 60 to 20 minutes).
- Addressable market of EUR 90-100 billion growing 3%-5% a year; WHO-estimated shortfall of more than 10 million health workers by 2030 drives demand for productivity.
- CFO Charlotte Hanneman: EUR 2.5 billion productivity delivered 2023-2025, a new EUR 1.5 billion programme, R&D at around 9% of sales ("fewer, bigger and better"), adjusting items to fall from around 200 basis points in 2026 to industry levels; leverage down from 3 times in 2022 to 1.7 times in 2025.
- Segment targets to 2028: Image Guided Therapy (EUR 3.5 billion revenue, about 45% global share) mid-to-high-single-digit growth and margin above 20%; Precision Diagnosis (EUR 5 billion) low-to-mid-single-digit growth, low-teens margin; Connected Care mid-teens margin; Personal Health (EUR 3.7 billion, 18% margin) mid-single-digit growth and high-teens margin.
- New platforms: Azurion Eye AI cath-lab software, SpectraWAVE coronary imaging, helium-free 3T MR, Verida AI spectral CT, a next-generation monitoring care intelligence platform.
- US sleep therapy re-entry is excluded from the plan ("the timing of this return is not in our control"); China treated cautiously; North America is the core growth engine (double-digit growth every quarter of 2025).

## Questions about Philips

### What does Philips do?

Philips is a health technology company selling imaging, image-guided therapy, patient monitoring and informatics to hospitals, and personal health products such as Sonicare toothbrushes and shavers to consumers.

### What is Philips' revenue?

FY2025 sales were EUR 17,834 million, up 2% comparable, with Adjusted EBITA of EUR 2,195 million. First-half 2026 sales were EUR 8,265 million.

### How many people work at Philips?

About 65,000 employees, in 71 countries, according to the 2025 annual report.

### What is Philips' strategy to 2028?

Mid-single-digit comparable sales growth, a mid-teens Adjusted EBITA margin in 2028, EUR 4.5-5.0 billion cumulative free cash flow and EUR 1.5 billion of productivity savings, with extra focus on Monitoring and Interventional and on AI-powered platforms.

### Who leads Philips?

Roy Jakobs has been CEO since October 2022, with Charlotte Hanneman as CFO; the Supervisory Board is chaired by Feike Sijbesma.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
